Skip to main
KRRO

KRRO Stock Forecast & Price Target

KRRO Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Korro Bio is a promising biopharmaceutical company with an innovative approach to genetic medicine. Their focus on editing RNA instead of DNA enables them to target a wider range of diseases and provide a more precise and tunable treatment. The company has shown promising results in their preclinical studies, with their lead drug candidate, KRRO-121, demonstrating effective ammonia reduction and minimal side effects in both mouse and non-human primate models. With a robust portfolio of programs and a solid financial position, Korro Bio has the potential for significant growth and success in the biopharmaceutical industry.

Bears say

Korro Bio is a relatively new company and has a small portfolio of differentiated programs in the early stages of development. Despite promising preclinical data and potential market exclusivity from orphan drug designations, the company faces significant competition in the biopharmaceutical industry. Additionally, the failure of its KRRO-110 AATD program and potential delays in advancing pipeline candidates in clinical trials could lead to downward pressure on the stock. There is also the risk of discrepancies between the Company’s interpretations of data and those of regulatory authorities, possibly limiting the potential indications for its therapeutic products.

KRRO has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Frequency Therapeutics Inc (KRRO) Forecast

Analysts have given KRRO a Buy based on their latest research and market trends.

According to 8 analysts, KRRO has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Frequency Therapeutics Inc (KRRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.